Trial
NCT03042325
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
Alogliptin
Why stopped
Business decision, no safety or efficacy concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-20